Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2CNS 1

Conditions

Sarcoma, Ewing 2Osteosarcoma 2Rhabdoid Tumor 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Diffuse Intrinsic Pontine Glioma 1

Interventions

Magnetic Resonance Spectroscopy 84Specimen Handling 83Cyclophosphamide 75pembrolizumab 64Radiotherapy 54Nivolumab 52fludarabine 44Cisplatin 40Biopsy 40Carboplatin 39Standard of Care 38Bevacizumab 32Dexamethasone 31Rituximab 29Gemcitabine 29venetoclax 27Surveys and Questionnaires 27Radiosurgery 27Radiation 27Temozolomide 26Practice Guidelines as Topic 26Paclitaxel 25Doxorubicin 25Blood Specimen Collection 25Cytarabine 24fludarabine phosphate 23Interviews as Topic 22atezolizumab 21Injections 20Capecitabine 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Eflornithine × 30 days × Clear all
NCT06465199 2026-06-12

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Milton S. Hershey Medical Center

Phase 1/2 Recruiting
289 enrolled
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Neuroblastoma, Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

NCT07321912 2026-06-12

Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

Milton S. Hershey Medical Center

Phase 2 Recruiting
406 enrolled
Sarcoma

Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡